SCHEMBL2265703

SCHEMBL2265703

Cc1cc(C#N)cc(Cl)c1Oc1ccnc(NC2CCN(c3cccc(CC#N)c3)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.40
CYP2C9 P11712 1/20 0.37
PSEN1 P49768 5/20 0.36
PSEN2 P49810 5/20 0.36
APH1B Q8WW43 5/20 0.36
NCSTN Q92542 5/20 0.36
APH1A Q96BI3 5/20 0.36
PSENEN Q9NZ42 5/20 0.36
MAPK10 P53779 2/20 0.36
DGAT1 O75907 1/20 0.35
VCP P55072 2/20 0.35
ACHE P22303 2/20 0.35
BACE1 P56817 2/20 0.35
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
PRMT8 Q9NR22 1/20 0.34
CRHR1 P34998 1/20 0.34
MAPK14 Q16539 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2262391 0.86 KCNH2 (0.41) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2261090 0.86 KCNH2 (0.48) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2260009 0.86 KCNH2 (0.39) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2261778 0.85 KCNH2 (0.41) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2259038 0.85 KCNH2 (0.42) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2265337 0.82 CYP2C9 (0.42) KCNH2CYP2C9VCPACHEBACE1
SCHEMBL2260938 0.81 KCNH2 (0.44) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2260086 0.80 KCNH2 (0.51) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2265459 0.80 KCNH2 (0.41) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2262129 0.79 IKBKB (0.44) KCNH2CYP2C9CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CYP2C9 1382/4885PSEN1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.